Journal of Clinical and Aesthetic Dermatology

MauiDerm Abstract Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/677940

Contents of this Issue

Navigation

Page 2 of 27

[ M AY 2 0 1 6 • V O L U M E 9 • N U M B E R 5 ] S U P P L E M E N T T O T H E J O U R N A L O F C L I N I C A L A N D A E S T H E T I C D E R M AT O L O G Y S3 S 3 ACNE Efficacy and Safety of Once-Daily Dapsone Gel 7.5% for Treatment of Adolescents and Adults with Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Placebo- Controlled Trials Presenters: 1 Linda F. Stein Gold, MD; 2 Michael T. Jarratt, MD; 3 Alicia D. Bucko, DO; 4 Steven K. Grekin, DO; 5 Joshua M. Berlin, MD; 6 Michael Bukhalo, MD; 7 Jonathan S. Weiss, MD; 8 David Berk, MD; 8 Joan-En Chang-Lin, PhD; 8 Vince Lin, PhD; 8 Alexandre Kaoukhov, MD Affiliations: 1 Henry Ford Medical Center, Detroit, MI; 2 DermResearch, Inc., Austin, TX; 3 Academic Dermatology Associates, Albuquerque, NM; 4 Grekin Skin Institute, Warren, MI; 5 Dermatology Associates, PA, of the Palm Beaches, Boynton Beach, FL; 6 Altman Dermatology Associates, Arlington Heights, IL; 7 Gwinnett Dermatology, PC, Snellville, GA; 8 Allergan plc, Irvine, CA Objective: Treatment of acne vulgaris with dapsone gel 5% requires twice-daily dosing. This first of two studies assessed efficacy and safety of a once-daily formulation of dapsone gel 7.5% (DAP) versus vehicle (VEH) over 12 weeks in patients with acne. Methods: This randomized, double- blind, multicenter study enrolled 2,102 patients (≥12y) with 20 to 50 inflammatory lesions, 30 to 100 noninflammatory lesions, and a moderate grade (3) on the Global Acne Assessment Score (GAAS). Investigator-assessed efficacy measures at Week 12 were GAAS success rate (GAAS = 0 or 1) and percent change from baseline in inflammatory, noninflammatory, and total lesions. Results: At Week 12, for DAP versus VEH, respectively, GAAS success rate was 29.9 percent versus 21.2 percent, mean inflammatory lesions decreased by 55.5 percent versus 49.0 percent, mean noninflammatory lesions decreased by 44.4 percent versus 38.4 percent, and mean total lesions decreased by 48.7 percent versus 42.4 percent (all P<0.001). AE incidence was 19.1 percent for DAP and 20.6 percent for VEH. Most AEs in both groups were mild to moderate in severity. Most patients receiving DAP and VEH had a severity rating of "none" on stinging/burning, dryness, scaling, and erythema scales at all time points. Conclusion: Dapsone gel 7.5% applied topically once daily is an effective, safe, and well-tolerated topical acne treatment. Efficacy and Safety of Once-Daily Dapsone Gel 7.5% for Treatment of Adolescents and Adults with Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Placebo- Controlled Trials Presenters: 1 Lawrence F. Eichenfield, MD; 2 Ted Lain, MD; 3 Ellen H. Frankel, MD; 4 Terry M. Jones, MD; J Clin Aesthet Dermatol. 2016;9(5 Suppl 1):S1–S24 Abstracts of Poster Presentations: MauiDerm 2016 January 25–29, 2016 • Grand Wailea • Maui, Hawaii The 2016 edition of the annual MauiDerm meeting had a wide variety of clinical and scientific data presented not only at the podium, but in its poster sessions as well. A wide range of clinically relevant material was presented in poster format. For those of you who were not on hand to review the posters and discuss them with their authors, we have compiled and indexed selected posters from the 2016 meeting. It is my hope that you will find the posters informative and thought provoking. For an alphabetical index organized by poster title or author, please see page 22 of this supplement. George Martin, MD Program Director, MauiDerm; Dermatology Laser Center Maui Kihei, Hawaii

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MauiDerm Abstract Supplement 2016